AstraZeneca “effective against British mutant virus”
Pfizer does not officially announce the effect of mutant virus in South Africa
A study result was announced on the 6th (local time) that AstraZeneca’s novel coronavirus infection (Corona 19) vaccine has limited effectiveness against the South African mutant virus. Courtesy of AstraZeneca
–
–
The Financial Times (FT) said on the 6th (local time) that the results of a clinical trial that a novel coronavirus infection (COVID-19, Corona 19) vaccine jointly developed by AstraZeneca and Oxford University in the UK has limited effectiveness against mutant viruses in South Africa. Reported.
As NovaVax and Janssen’s COVID-19 vaccines have also been reported to be ineffective against the South African mutant virus, the possibility that the South African mutant virus will emerge as an important variable in the global corona 19 epidemic has increased.
According to the Financial Times, the University of Oxford and the University of South Africa’s Bitbadersland divided a total of 2026 into two groups, each receiving a fake drug and AstraZeneca vaccine twice, and conducting a clinical trial to investigate the formation of antibodies. The average age of those who participated in the clinical trial is 31 years old.
As a result, it was found that the AstraZeneca vaccine did not prevent the mild and moderate expression of Corona 19 caused by the South African mutant virus. No effect on inpatient incidence or mortality was identified. Professor Tulio de Oliveira, head of the South African Genome Research Network, told The Financial Times “a warning that the world needs to control the virus and strengthen its response to COVID-19.”
Corona 19 vaccines that have obtained emergency approval for use so far or that have completed phase 3 clinical trials and are about to be approved for emergency use sooner or later are generally effective against the UK mutant virus, but are reported to be less effective against the South African mutant virus.
The AstraZeneca vaccine has also been shown to maintain immune effects against the British mutant virus. Andrew Pollard, who leads the development of the AstraZeneca vaccine, said on the 5th, “According to clinical trial data, the AstraZeneca vaccine protects the inoculum from a mutant virus that has caused a surge in confirmed cases across the UK since the end of last year. ”
On the other hand, results have been announced that most of the COVID-19 vaccines, including AstraZeneca, are ineffective against the South African mutant virus. Janssen, an affiliate of Johnson & Johnson, said its COVID-19 vaccine had an immune effect of 57% in South Africa, which was significantly lower than the results of clinical trials conducted in the United States (72%). NovaVax also said its COVID-19 vaccine was effective at 89% in the UK, but less effective at 60% in South Africa.
Modena also confirmed that the effectiveness of the vaccine against the South African mutant virus is significantly lower, and is developing a Corona 19 vaccine that targets the South African mutant virus. Pfizer said it had some ineffectiveness against viruses with mutations similar to those of the South African mutant virus, but did not publish test results for the South African mutant virus itself.
Meanwhile, AstraZeneca announced that it plans to update the Corona 19 vaccine to produce a vaccine that is effective against the mutant virus this fall.
In Korea, there were 51 cumulative confirmed mutant viruses as of 6 days, of which 37 cases were infected with the British mutant virus. Nine people are infected with the South African mutant virus and 5 people are infected with the Brazilian mutant virus.
– .
